Are IDEXX (USA Stocks:IDXX) investors starting to hold back?

IDXX Stock  USD 485.51  6.77  1.41%   
IDEXX Laboratories Calculated Tax Rate is fairly stable at the moment as compared to the past year. IDEXX Laboratories reported Calculated Tax Rate of 20.11 in 2022. PPandE Turnover is likely to rise to 6.48 in 2023, whereas Revenue Per Employee is likely to drop slightly above 253.9 K in 2023. Today's short post will break down IDEXX Laboratories as your potential position. We will inspect the question of why investors should continue to be confident in IDEXX Laboratories outlook.
Published over a month ago
View all stories for IDEXX Laboratories | View All Stories
Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

IDEXX Laboratories is UNDERVALUED at 635.03 per share with modest projections ahead. Over 93.0% of IDEXX Laboratories shares are owned by institutional investors. Institutional ownership of IDEXX Laboratories refers to the amount of IDEXX Laboratories equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of IDEXX, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as IDEXX Laboratories. Regardless of method or technology, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for IDEXX Laboratories

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of IDEXX Laboratories' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of IDEXX Laboratories in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as IDEXX Laboratories. Your research has to be compared to or analyzed against IDEXX Laboratories' peers to derive any actionable benefits. When done correctly, IDEXX Laboratories' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in IDEXX Laboratories.

How important is IDEXX Laboratories's Liquidity

IDEXX Laboratories financial leverage refers to using borrowed capital as a funding source to finance IDEXX Laboratories ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. IDEXX Laboratories financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between IDEXX Laboratories's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for IDEXX Laboratories, but it might be worth checking our own buy vs. sell analysis

Idexx Laboratories exotic insider transaction detected

Legal trades by IDEXX Laboratories insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Idexx insider trading alert for general transaction of common stock by Jonathan Ayers, the corporate stakeholder, on 8th of September 2022. This event was filed by Idexx Laboratories Inc with SEC on 2022-09-08. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.


IDEXX Laboratories currently demonstrates below-average downside deviation. It has Information Ratio of 0.15 and Jensen Alpha of 0.39. However, we advise investors to further question IDEXX Laboratories expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure IDEXX Laboratories' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact IDEXX Laboratories' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Returns Breakdown

Return on Assets
Return on Investment
Return on Investment43.89
Return on Assets23.08
Return on Equity151.22
Return Capital0.37
Return on Sales0.3

Will IDEXX pull back in March 2023?

IDEXX Laboratories current maximum drawdown rises over 15.44.
As of the 6th of February, IDEXX Laboratories retains the Risk Adjusted Performance of 0.1802, market risk adjusted performance of 0.2935, and Semi Deviation of 1.76. IDEXX Laboratories technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for IDEXX Laboratories, which can be compared to its competitors. Please check out IDEXX Laboratories mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if IDEXX Laboratories is priced more or less accurately, providing market reflects its last-minute price of 487.54 per share. Given that IDEXX Laboratories has jensen alpha of 0.393, we strongly advise you to confirm IDEXX Laboratories's regular market performance to make sure the company can sustain itself in the future.

Our Final Take On IDEXX Laboratories

While some firms within the diagnostics & research industry are still a little expensive, even after the recent corrections, IDEXX Laboratories may offer a potential longer-term growth to investors. To conclude, as of the 6th of February 2023, our overall 90 days buy-hold-sell advice on the company is Strong Buy. We believe IDEXX Laboratories is undervalued with very small probability of distress for the next two years.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of IDEXX Laboratories. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to